These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 19497172

  • 1. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Kumar A, Godoy G, Taneja SS.
    Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 3. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
    Loeb S, Roehl KA, Yu X, Han M, Catalona WJ.
    Urology; 2007 Jan 15; 69(1):108-12. PubMed ID: 17270629
    [Abstract] [Full Text] [Related]

  • 4. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
    BJU Int; 2012 Jun 15; 109(11):1627-35. PubMed ID: 21939492
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ.
    BJU Int; 2007 Apr 15; 99(4):753-7. PubMed ID: 17244286
    [Abstract] [Full Text] [Related]

  • 6. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D, Black A, Murray LJ, Nambirajan T, Keane PF, Gavin A.
    BJU Int; 2008 Jun 15; 101(12):1507-12. PubMed ID: 18341627
    [Abstract] [Full Text] [Related]

  • 7. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Bittner N, Merrick GS, Andreini H, Taubenslag W, Allen ZA, Butler WM, Anderson RL, Adamovich E, Wallner KE.
    Urology; 2009 Jul 15; 74(1):171-6. PubMed ID: 19232691
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb 15; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H, Nakamura M, Hasumi H, Sugiura S, Fujinami K, Miyoshi Y, Yao M, Kubota Y.
    Int J Urol; 2004 Jul 15; 11(7):494-500. PubMed ID: 15242358
    [Abstract] [Full Text] [Related]

  • 10. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.
    J Urol; 2005 Dec 15; 174(6):2191-6. PubMed ID: 16280762
    [Abstract] [Full Text] [Related]

  • 11. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH.
    Eur Urol; 2006 Mar 15; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [Abstract] [Full Text] [Related]

  • 12. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
    Loeb S, Roehl KA, Catalona WJ, Nadler RB.
    BJU Int; 2008 Apr 15; 101(7):817-21. PubMed ID: 18321315
    [Abstract] [Full Text] [Related]

  • 13. Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction.
    Choi SY, Chang IH, Kim YS, Kim TH, Kim W, Myung SC.
    Urology; 2011 Oct 15; 78(4):874-9. PubMed ID: 21791361
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV.
    Cancer; 2007 Nov 01; 110(9):1973-8. PubMed ID: 17886252
    [Abstract] [Full Text] [Related]

  • 15. Role of PSA and its indices in determining the need for repeat prostate biopsies.
    Ukimura O, Durrani O, Babaian RJ.
    Urology; 1997 Jul 01; 50(1):66-72. PubMed ID: 9218021
    [Abstract] [Full Text] [Related]

  • 16. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM.
    J Urol; 2007 Feb 01; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [Abstract] [Full Text] [Related]

  • 17. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev V, Broadwater G, Sun L, Mayes JM, Moul JW, Polascik TJ.
    Urology; 2008 Jun 01; 71(6):1020-3. PubMed ID: 18267331
    [Abstract] [Full Text] [Related]

  • 18. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A.
    Can J Urol; 2009 Jun 01; 16(3):4659. PubMed ID: 19497173
    [No Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
    Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC.
    J Clin Oncol; 2010 Jun 10; 28(17):2810-6. PubMed ID: 20439642
    [Abstract] [Full Text] [Related]

  • 20. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1128-33. PubMed ID: 16912265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.